Worldwide Clinical Trials acquires Catalyst Clinical Research

Worldwide Clinical Trials agreed to acquire Catalyst Clinical Research. Reported deal value: Undisclosed. Status: Pending. Sector: Contract Research Organization (CRO). Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-01-22. Figures and status may change as filings and press coverage update.

Sign in or Register 100% Headquartered in Durham , North Carolina , Worldwide Clinical Trials is a CRO When the deal closes, Nick Dyer, chairman of the board of Catalyst , will join Worldwide board of directors, and Nik Morton, president and CEO of Catalyst , will join Worldwide executive leadership team The transaction is expected to close in the first quarter of 2026 Worldwide Clinical Trials , which is backed by Kohlberg & Co, has agreed to acquire Catalyst Clinical Research , a portfolio company of QHP Capital